Tradegate
04.06.25 | 12:28
4,760 Euro
-1,24 % -0,060
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 4,720 | 4,880 | 04.06. | |
| 4,680 | 4,920 | 04.06. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08.05. | Silence Therapeutics plc GAAP EPS of -C$0.20 | 4 | Seeking Alpha | ||
| SILENCE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 08.05. | Silence Therapeutics plc - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 08.05. | Silence Therapeutics plc: Silence Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights | 927 | Business Wire | Company further extends cash guidance into 2028
Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global clinical-stage company developing novel siRNA (short interfering RNA)... ► Artikel lesen | |
| 06.05. | Silence Therapeutics plc - 8-K, Current Report | 3 | SEC Filings | ||
| 06.05. | Silence Therapeutics plc: Silence Therapeutics Welcomes Tim McInerney to Board of Directors | 328 | Business Wire | Mr. McInerney brings over 30 years of industry experience spanning senior executive, finance and capital advisory roles in the pharmaceutical and biotechnology sectors
Silence Therapeutics plc... ► Artikel lesen | |
| 30.04. | Silence Therapeutics plc - 10-K/A, Annual Report | 2 | SEC Filings | ||
| 24.04. | Silence Therapeutics plc (SLN): Among Takeover Rumors Hedge Funds Are Buying | 3 | Insider Monkey | ||
| 07.03. | H.C. Wainwright maintains $75 target on Silence Therapeutics stock | 3 | Investing.com | ||
| 05.03. | Silence Therapeutics plc: Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference | 304 | Business Wire | Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that management will present... ► Artikel lesen | |
| 05.03. | Morgan Stanley cuts Silence Therapeutics stock target to $45 | 4 | Investing.com | ||
| 04.03. | Deep Dive Into Silence Therapeutics Stock: Analyst Perspectives (7 Ratings) | 2 | Benzinga.com | ||
| 27.02. | Jefferies cuts Silence Therapeutics price target to $30 | 5 | Investing.com | ||
| 27.02. | Silence Therapeutics plc - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 27.02. | Silence Therapeutics plc - 10-K, Annual Report | - | SEC Filings | ||
| 27.02. | Silence Therapeutics plc - 8-K, Current Report | - | SEC Filings | ||
| 27.02. | Silence Therapeutics plc: Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update | 394 | Business Wire | The Company's cash guidance is now extended into 2027 Company to host conference call and webcast today at 8 a.m. EST 1 p.m. GMT
Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company")... ► Artikel lesen | |
| 13.02. | Silence Therapeutics plc: Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025 | 351 | Business Wire | Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that the Company will... ► Artikel lesen | |
| 11.02. | Silence Therapeutics hit with new Sell at Goldman Sachs on resource constraints | 10 | Seeking Alpha | ||
| 11.02. | Goldman Sachs cuts Silence Therapeutics stock rating to Sell | 5 | Investing.com | ||
| 03.02. | Deep Dive Into Silence Therapeutics Stock: Analyst Perspectives (7 Ratings) | 4 | Benzinga.com |
Seite:
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVO NORDISK | 63,88 | +2,01 % | Klare Kante aus Europa: Novo Nordisk und Co setzen ein Zeichen | Europa wird oft als schwerfällig, bürokratisch und wirtschaftlich träge abgestempelt. Doch ein genauer Blick auf die Börsenlandschaft zeigt: Inmitten globaler Unsicherheit befindet sich ein neues Kraftzentrum.... ► Artikel lesen | |
| GILEAD SCIENCES | 95,77 | +0,23 % | Gilead Sciences Commemorated the Opening of the Bay Area Young Survivors Breast Cancer Memorial Garden | NORTHAMPTON, MA / ACCESS Newswire / May 30, 2025 / Gilead Sciences:We recently commemorated the opening of the Bay Area Young Survivors Breast Cancer Memorial Garden in San Francisco's Golden Gate Park.... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 392,45 | +0,45 % | Vertex Pharmaceuticals-Aktie an der Börse auf der Verliererseite: Börsenkurs fällt deutlich (381,9154 €) | Im US-amerikanischen Wertpapierhandel fällt derzeit die Aktie von Vertex Pharmaceuticals negativ auf. Das Wertpapier verbilligt sich am Mittwoch deutlich. Ein Kurssturz auf zwischenzeitlich 433,39 US-Dollar... ► Artikel lesen | |
| INNOCAN PHARMA | 0,103 | -1,44 % | Breaking News: Innocan Q1-25 Zahlen! Mit Wachstum ins neue Jahr! | ||
| IONIS PHARMACEUTICALS | 30,360 | +2,67 % | Ionis Pharmaceuticals, Inc.: Ionis expands partnership with Sobi to include olezarsen commercialization outside the U.S. | - Agreement enables olezarsen to reach people living with conditions associated with elevated triglycerides across the world - - Ionis will continue to independently commercialize TRYNGOLZA (olezarsen)... ► Artikel lesen | |
| SNDL | 1,112 | -1,24 % | SNDL Inc.: SNDL Reports First Quarter 2025 Financial and Operational Results | The Company Delivers Record Gross Margin and Positive Cash Flow; Announces Strategic Review of U.S. Platform and Listing Structure
EDMONTON, AB, May 1, 2025 ... ► Artikel lesen | |
| ASSEMBLY BIOSCIENCES | 13,600 | -2,51 % | Assembly Biosciences, Inc.: Assembly Biosciences Reports First Quarter 2025 Financial Results and Recent Updates | - Ongoing clinical studies for four candidates on track with data expected in 2025, including interim Phase 1b data for long-acting helicase-primase inhibitors ABI-5366 and ABI-1179 anticipated in... ► Artikel lesen | |
| HAPPY BELLY FOOD GROUP | 0,680 | +0,74 % | Happy Belly Food Group Inc.: Happy Belly Food Group's Smash Burger Brand Rosie's Burgers Announces the Signing of its First Franchise Agreement in Atlantic Canada for the City of Halifax, Nova Scotia | Toronto, Ontario--(Newsfile Corp. - June 3, 2025) - Happy Belly Food Group Inc. (CSE: HBFG) (OTCQB: HBFGF) ("Happy Belly" or the "Company"), a leading consolidator of emerging food brands is pleased... ► Artikel lesen | |
| ALNYLAM PHARMACEUTICALS | 264,70 | -1,05 % | H.C. Wainwright bestätigt Kursziel für Alnylam-Aktie bei 500 US-Dollar | ||
| LIGAND PHARMACEUTICALS | 88,00 | -3,30 % | ROUNDUP: Ligand Pharmaceuticals Reiterates FY25 Outlook | WASHINGTON (dpa-AFX) - While reporting financial results for the first quarter on Thursday, biopharmaceutical company Ligand Pharmaceuticals, Inc. (LGND) reiterated its adjusted earnings and... ► Artikel lesen | |
| DARE BIOSCIENCE | 3,100 | +0,32 % | Daré Bioscience partners with Rosy Wellness for new women's health cream | ||
| MEI PHARMA | 2,190 | +0,46 % | MEI Pharma Reports Second Quarter Fiscal Year 2025 Cash Position | SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP) (the "Company") today reported results for its quarter ended December 31, 2024.
As previously announced in July 2024, the Company is... ► Artikel lesen | |
| HYTN INNOVATIONS | 0,114 | 0,00 % | Von nichts auf bald zweistellige Millionenbeträge? - Breaking News: Wichtige Genehmigung erteilt! | ||
| WAVE LIFE SCIENCES | 5,550 | -5,13 % | Wave Life Sciences Ltd.: Wave Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update | Dosing complete in the first two cohorts of INLIGHT trial in obesity of WVE-007 (INHBE siRNA), designed to induce healthy weight loss by reducing fat without impacting muscle; clinical data on track... ► Artikel lesen | |
| AKARI THERAPEUTICS | 1,090 | -5,22 % | Akari Therapeutics Plc: Akari Therapeutics Releases "Meet the Team" Video Featuring Recently Appointed Mark F. Kubik, Head of Business Development - Oncology |
SILENCE THERAPEUTICS PLC ADR gehört der Branche Pharma an. Mit einer aktuellen Kursveränderung von -0,060 (-1,24 %) liegt der Kurs bei 4,760 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SILENCE THERAPEUTICS PLC ADR finden Sie auf Wallstreet Online.